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A R T I C L E  I N F O A B S T R A C T
Article type:Original article Objective(s): In addition to pro-inflammatory role, dendritic cells (DCs) can also be anti-inflammatory when they acquire tolerogenic phenotype. In this study we tested the role of CD40 and IL-23p19 in 
antigen presenting function of bone marrow-derived DCs (BMDCs) by comparing BMDCs derived 
from CD40 knockout (CD40KO-DCs) and IL-23p19 (IL-23p19KO-DCs) knockout mice with those 
from C57BL/6 mice (Cont-DCs). We have focused on CD40 and IL-23, as these molecules have well 
established pro-inflammatory roles in a number of autoimmune and inflammatory diseases.  Materials and Methods: The expression of maturation markers MHC II and co-stimulatory molecules CD40, 
CD80, and CD86 was analyzed by flow cytometry, while the expression of CD40 and IL-23p19 was measured 
by RT-PCR. The capacity of BMDCs to activate CD4+ T cells was evaluated by 3H-thymidine incorporation, 
and the capacity of BMDCs to uptake antigen was evaluated using fluorescent OVA and flow cytometry. 
Results: The lack of CD40 or IL-23p19 had no effect on uptake of FITC-OVA by the DCs, confirming 
their immature phenotype. Moreover, CD40KO-DCs had significantly reduced capacity to stimulate 
proliferation of CD4+ T cells. CD4+ T cells activated by CD40KO-DCs and IL-23p19KO-DCs produced 
significantly less IFN-γ (P-value ≤0.05), while CD4+ T cells stimulated by IL-23p19KO-DCs produced 
less GM-CSF and more IL-10 than Cont-DCs. 
Conclusion: This study shows that CD40KO-DCs and IL-23p19KO-DCs have a marked tolerogenic potency in vitro. Future in vivo studies should determine if and to what extent DCs lacking CD40 or 
IL-23 have a potential to be useful in therapy of autoimmune inflammation. 
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Introduction
Dendritic cells (DCs) have the capacity to either initiate and perpetuate immune responses as 
professional antigen-presenting cells (APCs), or to potently dampen immune responses if they acquire 
tolerogenic phenotype (1-3). The ability of DCs to activate T cell responses depends on three signals: 
1. peptide-major histocompatibility complex (MHC) 
complexes (signal 1); 2. co-stimulatory molecules (signal 
2); and 3. cytokine production (signal 3). These three signals collectively provide a complete stimuli for T cell 
activation and differentiation (4). However, depending 
on the nature of the above signals, DCs can either fail to initiate new T cell response, or they can actively suppress ongoing response through various mechanisms, such as 
the induction of Treg cells (4). Tolerogenic DCs express 
fewer co-stimulatory molecules and pro-inflammatory 
cytokines (5, 6), while up-regulating inhibitory cell-
surface molecules and producing greater levels of anti-
inflammatory cytokines such as IL-10 (6) and TGF-β (7). 
Since their discovery in 2005, Th17 cells took a central role as mediators of autoimmunity in a number of diseases, such as type 1 diabetes, rheumatoid arthritis, and experimental autoimmune encephalomyelitis 
(EAE), an animal model of multiple sclerosis (MS) 
(8-10). It has been shown that CD40, a pivotal DC costimulatory molecule, is critical to both DC maturation 
and Th17 cell development (11, 12). Furthermore, IL-
23, a heterodimeric cytokine formed by pairing of IL-
23p19 and IL-12/23p40 subunits, which is secreted 
by DCs, is essential to the development of pathogenic Th17 cell responses and autoimmune diseases, such as 
EAE and rheumatoid arthritis diseases (13, 14). Several 
studies have shown that suppression of CD40 or IL-
23 production by DCs prevents development of Th1/Th17 responses and autoimmunity (13-17).  In our previous  study, we found that BMDCs with lentiviral-
driven double knockdown of CD40 and IL-23p19 had 
tolerogenic effect due to down-regulation of CD40, 
lower expression of IL-6 and IL-12 and increased IL-10 
production (18). In the present study, we extend these 
findings by testing DCs that completely lack CD40 and 
IL-23p19 due to genetic knockout. IL-10-treated DCs were used for comparison, as well established model 
for tolerogenic DCs (19). Overall, the lack of CD40 led 
to significant but moderate reduction in proliferation 
of CD4+ T cells, while IFN-γ production was markedly reduced. The lack of IL-23p19 led to reduction in GM-
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CSF production and an increase in IL-10 production. 
Materials and Methods
Mice
C57BL/6, CD40 KO, and 2D2 mice were purchased 
from Jackson Laboratory (Bar Harbor, ME, USA). 2D2 
mice are transgenic for T cell receptor (TCR) specific for myelin oligodendrocyte glycoprotein peptide 
(MOG
35-55
) and CD40 KO mice on C57BL/6 background 
were homozygous for the targeted mutation. 
CD40 homozygous mutant mice exhibit impaired immunoglobulin class switching and germinal center 
formation. IL-23p19 KO mice on C57BL/6 background 
were homozygous for the targeted mutation and 
obtained from NIH: MMRRC. All animal studies were 
carried out with approval of the Institutional Animal 
Care and Use Committee of Thomas Jefferson University.
Generation of mouse BMDCs 
BMDCs were generated from BM progenitors by cutting both ends of the femur and tibia bones with 
scissors and flushing out the marrow using RPMI 1640 
(20). After passing BM cell suspension through nylon 
mesh (100 µm), the cells were washed by centrifuging 
at 1500 rpm for 4 min at 4 °C. The supernatant was 
removed and 2 ml RBC lysis buffer was added to the 
cell pellet. BM cells (6x106) were plated and incubated 
at 37 °C in 10 cm bacterial petri dish (low binding 
plates) for 3 days using complete RPMI medium 
supplemented with 10% FBS (CM10), L-glutamine (4 
mM), penicillin (100 μg/ml), streptomycin (100 μg/
ml), 50 μM 2-mercaptoethanol,  and 10 ng/ml GM-CSF. 
Non-adherent and semi-adherent cells were collected 
from the petri dishes on days 3, 6, and 9 using 0.025% 
Trypsin-EDTA solution.  BM cell cultures were pulsed 
for 24 hr with LPS (20 ng/ml; Sigma-Aldrich) on day 
10, for the process of DC maturation. The BM cells were 
cultured for 2 additional days in CM10 containing 10 
ng/ml GM-CSF and 30 ng/ml IL-10 to be differentiated 
into immature IL-10 DCs (21).
Flow cytometric analysis
Cultured cells were washed, suspended at 1x106 in 100 
µl of PBS containing 1% FBS, 0.15% sodium azide, and 2 
mM EDTA. To block Fc receptor, BMDCs were incubated 
with anti-CD16/32 antibody for 15 min on ice. The cells 
were then stained for 30 min at 4 °C with conjugated 
rat anti-mouse CD11c, MHC class II (IA/IE), CD80 and 
CD86 or the appropriate isotype controls. All antibodies 
were purchased from BD Biosciences (San Jose, CA, 
USA).  Stained cells were analyzed with BD fluorescence 
activated cell sorter (FACS) Aria (BD Biosciences) using 
BD FACSDiVa software (BD Biosciences).
RNA isolation, cDNA synthesis and quantitative real 
time polymerase chain reaction (qRT–PCR)According to the manufacturer’s instructions (Qiagen, 
Calencia, CA, USA) total RNA was extracted from samples using the RNeasy kit and then cDNA synthesis 
was done (Applied Biosystems, Grand Island, NY, USA). 
Quantitative PCR was carried out for each sample in a 
final reaction mixture of 20 μl containing 10 μl TaqMan® 
Universal PCR Master Mix (Applied Biosystems), 9 μl 
cDNA and 1 μl of each primer. 6-Carboxyfluorescein 
(FAM)-labeled primers were used for genes IL-23p19 
(IL-23a, Mm00518984_m1), CD40 (Mm00441891_
m1) and 18S ribosomal rRNA endogenous control 
(Hs99999901_s1).  The PCR was performed with the following conditions: the sample mixture was heated 
to 95 °C and held for 10 sec as an initial denaturation 
step, followed by 40 cycles of 5 sec at 95 °C denaturing 
temperature, 15 sec at 55 °C annealing temperature and 
1 min at 60 °C extension temperature on the sequence 
detection system 7000 (Applied Biosystems).
Cytokine measurement and antigen uptake assays
Levels of interferon (IFN)-γ, IL-17, IL-12p70, IL-23, 
IL-6, IL-10, and GM-CSF in cell culture supernatants were 
measured by ELISA, according to the manufacturer’s 
instructions (R&D Systems, Minneapolis, MN, USA; and 
Biolegend Systems, San Diego, CA, USA). To check the antigen uptake capacity, 10×105 of DCs were incubated 
with ovalbumin (OVA)-FITC at a final concentration of 
2 μg/ml. Control tubes were kept on ice and sample 
tubes were incubated at 37 °C for 30 min. After washing, 
uptake of OVA-FITC was determined by flow cytometry.
Statistical analysisGene expression, cytokine levels and proliferation 
assays were analyzed by Mann–Whitney U-test. 
Differences were considered statistically significant if P 
< 0.05. All analyses were performed using spss version 
17.0 or Graphpad Prism™ version 5.0 software.
Results
CD40KO and IL-23p19KO BMDC have similar surface 
phenotype as WT BMDCs 
To characterize phenotype of BMDCs after LPS 
maturation, expression of MHC II, CD40, CD80 and 
CD86 was evaluated by flow cytometry (Figure 1). 
The proportion of positive cells for MHC II, CD80 and 
CD86 in the CD40KO and IL-23p19KO DCs was similar 
to Cont-DCs. IL-10-treated BMDCs had much reduced 
 
  Figure 1. CD40KO and IL-23p19KO BMDC have similar surface 
phenotype as WT BMDCs. (Figure )
CD40KO, IL-23P19KO, IL-10 treated-, and Cont-DCs were treated with 
LPS and looked over for expression of MHC II and co-stimulatory molecules. Solid histograms show background staining with isotype 
control monoclonal antibody, and empty histograms represent specific 
staining of the indicated cell-surface markers
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expression of CD40, CD80, and MHC II, while expression 
of CD86 was reduced to a lesser extent. 
CD40KO and IL-23p19KO BMDCs have normal 
capacity for uptake of soluble antigen
The capacity of BMDCs to uptake soluble antigen was 
evaluated using FITC-OVA. As shown in Figure 2, the 
proportions of FITC+ cells among CD40KO, IL-23p19KO, 
IL-10-treated, and control BMDCs were similar. High 
endocytic capacity of CD40KO-, IL-23p19KO-, and IL-10-
DCs confirmed an immature state of these DCs.
CD40KO and IL-23p19KO BMDCs produce less pro-
inflammatory cytokines
To explore possible changes in cytokine profile of 
transduced BMDCs, levels of IL-23, IL-12p70 and IL-10 
in culture supernatant of BMDCs were evaluated after 
LPS stimulation on day 10. For IL-23 measurement, 
supernatants were tested 6 hr after LPS stimulation, 
whereas IL-12p70 and IL-10 were tested 24 hr after 
stimulation (sec 3. A, B, C, and D). IL-10-treated DCs 
produced moderately lower quantities of IL-23 than 
Cont-DCs. CD40KO and IL-10-treated DCs produced 
significantly less IL-12 than Cont-DCs, while IL-23p19KO 
DCs also produced less IL-12 (~50%) but this reduction 
did not reach statistical difference. In the case of IL-6, 
all three DC groups (CD40KO-, IL-23p19KO-, and IL-10-
DCs) produced significantly less of this cytokine (IL-6) 
 
  
Figure 2. CD40KO and IL-23p19KO BMDCs have normal capacity for uptake of soluble antigen
BMDCs were incubated in medium containing 1 mg/ml of fluorescein 
isothiocyanate-ovalbumin (FITC-OVA) for 30 min at 37 °C (A) or 4 °C 
(B) and analyzed by flow cytometry. Solid histograms show isotype control staining, whereas empty histograms show cells staining either 
at 37 °C or 4 °C
 Mean±SD 
  (pg/ml) 
              P-values 
             Cont-DCs 
   CD40KO-DCs     262±47                  0.028   
    P19KO-DCs   236±74                  0.052    
    IL-10-DCs   252±50                   0.03 
    Cont-DCs 
 
  811±13                   1.0 
 
 
  
Table 1. Interferon (IFN)–γ production by CD4+ T cells co-cultured 
with KO or IL-10-treated DCs in comparison to Cont-DCs group
KO: knockout; Cont-DCs: BMDCs derived from C57BL6 mice; Cont: control;  sd: standard deviation
 
  
Figure 3. CD40KO and IL-23p19KO BMDCs produce less pro-inflammatory cytokines. Cultures of CD40KO, IL-23p19KO and IL-10-treated DCs 
were pulsed with LPS on day 10 of culturing and their supernatants were analyzed by ELISA for IL-23 (A), IL-12p70 (B), IL-10 (C), and IL-6 (D). 
Results shown are representative of two independent experiments. Levels of CD40 and IL-23p19 mRNA expression were normalized with that of 
18S mRNA expression (E, F). Bars represent mean values±SEM. *P<0.05 and **P<0.01 represents statistically significant difference between test 
DC groups and Cont-DC group. The mean value and SEM of four independent quantitative RT-PCR experiments are shown
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than Cont-DCs. IL-10-treated DCs produced significantly 
more IL-10 than Cont-DCs, whereas IL-23p19KO and 
CD40KO DCs produced similar quantities of IL-10 as 
Cont-DCs.    
In addition to cytokine concentrations, mRNA levels 
of CD40 and IL-23p19 subunits were measured by 
quantitative RT-PCR in KO-derived DCs and compared 
to the control group. IL-10-treated DCs expressed 
significantly less of mRNA expression for both CD40 and 
IL-23p19 compared to Cont-DCs (P=0.025 and P=0.04, 
respectively) (Figure 3E and F). 
CD40KO and IL-23p19KO BMDCs have reduced 
capacity to stimulate IFN-γ production by CD4+ T cells 
To test the effect of CD40 and IL-23p19 KO on the 
capacity of DCs to mediate activation and proliferation 
of CD4+ T cells, we co-cultured CD40KO and IL-23p19KO 
BMDCs with CD4+ T cells from 2D2 mice (specific for 
MOG
35-55 
peptide). Even though both KO DCs exhibited modestly reduced capacity to promote T cell proliferation 
this reduction achieved significance only in the case of 
CD40KO DCs (Figure 4A). In contrast, IL-10-treated DCs failed to induce proliferation of T cells almost entirely.   
In addition to proliferation, we also tested cytokine 
production in DC-T cell co-cultures, as another measure 
of DCs’ capacity to activate T cells. In co-cultures with 
both types of KO and IL-10-treated DCs IFN-γ levels 
were sharply reduced compared with those with Cont-
DCs (Figure 4B and Table 1). Furthermore, co-cultured 
cells produced significantly less GM-CSF (Figure 4C and 
Table 2) and more IL-10 (Figure 4D and Table 3) in co-
culture with IL-23p19KO DCs than with the Cont-DCs.
 
Figure 4. CD40KO and IL-23p19KO BMDCs have reduced capacity to stimulate IFN-γ production by CD4+ T cells. A) CD40KO, IL-23p19KO and IL-
10-treated DCs were co-cultured with 2D2 CD4+ T cells at a T cell:DC ratio of 4:1 for 3 days. 3H-thymidine was added to the cultures for the last 24 
h. Data are presented as the mean values of triplicate cultures±SEM.  B), C), and D) IFN-γ, GM-CSF, and IL-10 were measured in the supernatants of 
separate CD4+ T cell-DC co-cultures by ELISA. *P<0.05 and **P<0.01 represent statistically significant difference between test co-cultures with test 
DCs and Cont-DCs. The results shown are representative of two independent experiments
 Mean±SD 
  (pg/ml) 
               P-values 
             Cont-DCs 
  CD40KO-DCs  537±23                   0.068 
   P19KO-DCs  413±13                   0.007 
   IL-10-DCs  562±28                   0.16 
   Cont-DCs 
 
 617±17                   1.0 
 
 
  
Table 2. GM-CSF production by CD4+ T cells co-cultured with KO or 
IL-10-treated DCs in comparison to Cont-DCs group
KO: knockout; Cont-DCs: BMDCs derived from C57BL6 mice; Cont: control; SD: standard deviation
 Mean±SD 
  (pg/ml) 
              P-values 
             Cont-DCs 
   
  CD40KO-DCs   132±19                   0.72 
   P19KO-DCs   200±16                   0.047 
   IL-10-DCs   173±11                  0.099 
   Cont-DCs 
 
  119±19                   1.0 
  
Table 3. IL-10 production by CD4+ T cells co-cultured with KO or IL-
10- treated DCs in comparison to Cont-DCs
KO: knockout; Cont-DCs: BMDCs derived from C57BL6 mice; Cont: control; SD: standard deviation
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Discussion
In the current study, we showed a tolerogenic effect 
for DCs lacking CD40 and IL-23p19. In our previous study, we showed a promising approach to make stable 
tolerogenic DCs by inhibiting CD40 or IL-23 gene 
expression in DCs with their specific shRNAs (18). In 
fact, to compare the effect of CD40 and IL-23p19 down-regulation by shRNA with their knockout counterparts, 
we used BMDCs derived from CD40KO and IL-23p19KO 
mice. In addition, BMDCs treated with IL-10 were used as a positive control. The next step in the study was 
testing tolerogenic characteristics of these BMDCs. 
Application of  tolerogenic DC therapies for autoimmune disorders was derived from the concept that maturation 
conditions determine the tolerogenicity of DCs. Many different methods are available for in vitro generation of 
DCs with tolerogenic function  while the most important goal in choosing the adquate method is to maintain 
DCs in a permanently immature state (22). Tolerogenic 
DCs lack second or third signals required for T cell 
activation. In fact, antigen presentation by tolerogenic 
DCs may culminate in T cell apoptosis, anergy or 
Treg cell differentiation (23). CD40 is one of the key 
co-stimulatory molecules for generating TDCs (24). 
CD40, a member of the tumor necrosis factor receptor 
(TNFR) superfamily is induced upon DC maturation 
(25). The original concept that immature DCs with very 
low levels of costimulatory molecules such as CD40 
induce tolerance, whereas mature DCs with increased 
expression of co-stimulatory molecules induce 
immunity (26-29) has been revised to the new concept 
that tolerance is induced by immature DCs producing IL-
10 (30, 31). It has been shown that exposure of ex vivo 
prepared DCs to antigens in the absence of complete maturation stimuli can prevent autoimmune diseases 
(9).
Our results show that after LPS activation of BMDCs, 
there was no significant difference in the percentage 
of positive cells for MHCII, CD86, and CD80 between 
knockout (CD40KO and IL-23p19KO) DCs.
One of the major DC functions regulated by CD40 
ligation is the production of cytokines. In DCs, CD40 
ligation through TRAF6 signaling leads to activation of 
NF-κB and production of cytokines such as IL-12p40 
and IL-6 (32). It is therefore possible that suppression 
of CD40 expression using KO technology may prevent 
non-canonical NF-κB signaling and result in inhibition 
of IL-6 and IL-12p40 production and subsequent Th17 
suppression. Consistent with this hypothesis, DCs from 
TRAF6 KO mice were unable to produce IL-6 or IL-12p40 
in response to CD40 engagement (33). This shows a key 
role of NF-κB signaling in CD40 function. Based on our 
data from uptake assay, in the absence of LPS stimulation there was no difference between the endocytic activity 
of knockout DCs and Cont-DCs, as negative control, or of 
IL-10-DCs, as positive control. 
Our results from DCs derived from KO mice, or treated 
with IL-10, showed an IL-12 reduction in all DCs groups 
in comparison to Cont-DCs. In addition, IL-23 and IL-6 
also showed significantly lower expression in all the 
above mentioned DC groups. Consistent with our results, several studies have demonstrated reduced production 
of pro-inflammatory cytokines such as IL-12 and IL-
23 and increased production of anti-inflammatory 
cytokines such as IL-10 in tolerogenic DCs (34, 35). 
In addition, when we tested the capacity of KO-derived 
DC and IL-10-DC groups to stimulate MOG-specific CD4+ 
T cells, MOG-pulsed CD40KO-derived and IL-10-treated 
DCs failed to promote IFN-γ production by T cells. In addition, co-cultured cells produced a significantly 
lower amount of GM-CSF and a higher amount of IL-10 
when co-cultured with IL-23p19KO-DCs compared to 
those T cells co-cultured with the Cont-DC group. Taken 
together, these results suggest that tolerogenic DCs 
can modulate antigen-specific CD4+ T cell responses, 
reducing their proliferation and polarizing their pro-
inflammatory cytokine profile into an anti-inflammatory 
one. In our previous work, we found that DCs transduced 
with lentiviral vectors that contain specific shRNAs for 
CD40, IL-23P19, and CD40+IL-23P19 can be considered 
as TDCs, even though shRNAs for both CD40+IL-23P19 
had the most potent TDCs (18).
ConclusionWe found no differences in comparison with previous studies on tolerogenic DCs treated with IL-10 in 
expression of molecules of CD80, CD86, CD40, and MHC 
II which the all DCs treated with IL-10 showed lower 
expressions of the four surface molecules. In addition, 
CD40KO-DCs only showed deficient expression of CD40 
with no decrease in other surface markers, while IL-
23p19KO-DCs revealed no reduction in expression 
of CD40 surface markers compared with cont-DCs. 
Nevertheless, IL-23p19KO-DCs showed low secretions 
of pro-inflammatory cytokine IL-6, while CD40KO-
DCs represented reduced levels of pro-inflammatory 
cytokines of IL-12 and IL-6. Although IL-10-DCs were 
the only DCs which produced IL-10 with a significantly 
increased level, CD40KO and IL-23p19KO DCs also 
showed higher expression of IL-10 compared to Cont-
DCs. Taken together, these data show that shifting from 
pro-inflammatory cytokines such as IL-6, IL12, and IL-23 
to anti-inflammatory cytokines like IL-10 may transform 
CD40KO and IL-23p19KO DCs into tolerogenic DC. We suggest that further in-vivo studies be conducted 
using these KO-derived DC to check their tolerogenic effect in therapy of EAE. 
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